[Abbott proposes in Europe and the U.S.A. the approval of Humira (adalimumab) for therapy of juvenile idiopathic arthritis. Pediatric clinical trial shows very promising results in juvenile rheumatoid arthritis].
Shandwick
Weber
W
Bude
Susanne
S
D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D017326:Clinical Trials, Phase III as Topic; D003424:Crohn Disease / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005060:Europe; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D010919:Placebos; D000068879:Adalimumab; D008727:Methotrexate